10 Aug 2018 10:00
For immediate release | 10 August 2018 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Total Voting Rights
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.
As at 31 July 2018 the Company's issued share capital consists of 515,127,294 Ordinary Shares of 1p each.
The total number of voting rights in the Company is 515,127,294 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information:
Alliance Pharma plc Peter Butterfield, Chief Executive Officer Andrew Franklin, Chief Financial Officer www.alliancepharma.co.uk
| + 44 (0) 1249 466966 |
Buchanan Mark Court / Sophie Wills / Gemma Mostyn-Owen
| + 44 (0) 20 7466 5000 |
Numis Securities Limited Nominated Adviser: Michael Meade / Freddie Barnfield Corporate Broking: James Black / Toby Adcock
| + 44 (0) 20 7260 1000 |
Investec Bank plc Corporate Finance: Daniel Adams / Ed Thomas Corporate Broking: Patrick Robb / Rob Baker
| +44 (0) 20 7597 5970 |
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Alliance Pharma (APH)